glp-1 news nov 2025 weight loss drug november Weight-Loss Drugs Could Address a Range of Addictions GLP-1 Trends: Access & Shortages, – Alarming rise in weight loss

However, lean body mass also includes organs, bones, and skin

It is interesting to note that the efficacy of Tirzepatide evaluated on a 7-point daily glucose profile demonstrated better control at all points of the glycemic profile compared to semaglutide 1 mg [3]

Like most side effects of weight-loss medications, it may pass with time, but it can be a sign of more significant issues such as kidney complications

This helps the body manage glucose more efficiently after meals (NIH)

While this strategy removes a tool that a doctor might use to treat weight loss in a patient, for some health plans, this may be the best way of keeping GLP-1s available to members with more serious conditions, while keeping premiums low enough that members can afford them

Both companies are simultaneously investing in digital health ecosystems Lilly Direct and Novo Nordisks digital engagement platforms embedding GLP-1 drug access within broader patient infrastructure